Watch out Claritin: Aldeyra announces clean sweep in PhIII for new allergy drug
Aldeyra Therapeutics’ stock $ALDX is surging after they posted sweeping results in a Phase III trial for their lead therapy.
Aldeyra announced Tuesday that the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
